The Global Drug Facility and its role in the market for tuberculosis drugs

The Lancet

Volumn 382, Issue 9901, 2013, Pages 1373-1379

  Arinaminpathy, Nimalan ^a   Cordier Lassalle, Thierry ^b   Vijay, Anant ^b   Dye, Christopher ^b  

^a PRINCETON UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; DRUG MARKETING; HEALTH CARE ACCESS; HEALTH CARE QUALITY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY CONTROL; TUBERCULOSIS;

EID: 84885854104     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60896-X     Document Type: Note

References (29)

1. World Health Organization. Global tuberculosis report 2012. http://www.who.int/tb/publications/globalreport/en/(accessed March 3, 2013).
2. Styblo K, Bumgarner JR. Tuberculosis can be controlled with existing technologies: evidence. In: Tuberculosis Surveillance Research Unit, Progress Report. The Hague: Tuberculosis Surveillance Research Unit, 1991: 60-72.
3. World Health Organization. An expanded DOTS framework for effective tuberculosis control. Int J Tuberc Lung Dis 2002; 6: 378-88.
4. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293: 2767-75.
5. WHO. Global Tuberculosis Programme. Report of the ad hoc-committee on the tuberculosis epidemic: London, 17-19 March, 1998. Geneva: World Health Organization, 1998.
6. Stop TB Partnership. Falling short: ensuring access to simple, safe and effective first-line medicines for tuberculosis. 2011. http://www. stoptb.org/assets/documents/resources/publications/technical/Falling Short.pdf (accessed March 3, 2013).
7. Stop TB Partnership. Global Plan to Stop TB, Phase I: 2001 to 2005. 2001. http://www.stoptb.org/assets/documents/global/plan/GLOBAL-PLAN-TO-STOP-TB-2001 2005.pdf (accessed March 3, 2013).
8. Raviglione MC. The Global Plan to Stop TB, 2006-2015. Int J Tuberc Lung Dis 2006; 10: 238-39.
9. Kumaresan J, Smith I, Arnold V, Evans P. The Global TB Drug Facility: innovative global procurement. Int J Tuberc Lung Dis 2004; 8: 130-38.
10. Matiru R, Ryan T. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management. Bull World Health Organ 2007; 85: 348-53.
11. Butler D. Fresh start for global disease fund. Nature 2012; 491: 508.
12. Maxmen A. Malaria plan under scrutiny. Nature 2012; 490: 13-14.
13. Stop TB Partnership (2011). The Global Plan to Stop TB 2011-2015. http://www.stoptb.org/global/plan/main/part2.asp (accessed March 3, 2013).
14. Global Drug Facility. Quality Assurance Policy and Procedures. July, 2010. http://www.stoptb.org/assets/documents/gdf/drugsupply/ GDF%20QA%20Policy%20and%20Procedures.pdf (accessed March 3, 2013).
15. Global Drug Facility. Annual Report 2010. http://www.stoptb.org/assets/ documents/gdf/whatis/GDF%20Anuual%20Report%202010. pdf (accessed March 3, 2013).
16. Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 2013; 17: 308-11.
17. Sabot O, Hall S. One more reason to fund the Global Fund. Lancet 2012; 379: e25-26.
18. Waning B, Kyle M, Diedrichsen E, et al. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health 2010; 6: 9.
19. Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3: S292-300.
20. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-87.
21. Hanif SN, Eldeen HS, Ahmad S, Mokaddas E. GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. Int J Tuberc Lung Dis 2011; 15: 1274-75.
22. Stop TB Partnership. DOTS Expansion Working Group Strategic Plan 2006-2015. http://whqlibdoc.who.int/hq/2006/WHO-HTM-TB-2006.370-eng.pdf (accessed March 3, 2013).
23. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011; 37: 978-81.
24. World Health Organization. Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. 2011. http://www. who.int/tb/features-archive/surveyTBdrugeuro/en/index. html (accessed March 3, 2013).
25. Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One 2011; 6: e18964.
26. Portero JL, Rubio M. Private practitioners and tuberculosis control in the Philippines: strangers when they meet? Trop Med Int Health 2003; 8: 329-35.
27. Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLoS One 2010; 5: e12023.
28. Uplekar M. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis 2003; 83: 156-64.
29. World Health Organization. Engaging all health care providers in TB control: guidance on implementing public-private mix approaches. 2006. http://www.who.int/tb/publications/2006/who-htm-tb-2006-360/en/index.html (accessed March 3, 2013).